A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : 1,5-AG / 1,5-anhydroglucitol

[Related PubMed/MEDLINE]
Total Number of Papers: 128
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   1,5-AG  (>> Co-occurring Abbreviation)
Long Form:   1,5-anhydroglucitol
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2016 1,5-Anhydro-D-Glucitol Could Reflect Hypoglycemia Risk in Patients with Type 2 Diabetes Receiving Insulin Therapy. CGMS, T2DM
2016 Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality. ARIC
2016 Do glycemic marker levels vary by race? Differing results from a cross-sectional analysis of individuals with and without diagnosed diabetes. ---
2016 Lower 1,5-anhydroglucitol is associated with adverse clinical events after percutaneous coronary intervention. CAD, Hb, PCI, TLR
2016 Measurement of 1,5-anhydroglucitol in blood and saliva: from non-targeted metabolomics to biochemical assay. ---
2016 Measurement of Postmortem 1,5-anhydroglucitol in Vitreous Humor for Forensic Diagnosis. CSF
2016 Racial Differences in and Prognostic Value of Biomarkers of Hyperglycemia. ARIC, CVD, ESRD
2016 Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia-1,5-anhydroglucitol, fructosamine, and glycated albumin. 2hG, BMI, FA, GA, HbA1c, OGTT, ROC, ROC-AUCs
2015 1,5-ANHYDROGLUCITOL AND NEONATAL COMPLICATIONS IN PREGNANCY COMPLICATED BY DIABETES. BMI, NBW, T1DM, T2DM
10  2015 1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes. CGMS, HbA1c, MAGE, SD
11  2015 Ability of 1,5-Anhydro-d-glucitol Values to Predict Coronary Artery Disease in a Non-Diabetic Population. CAD, HbA1c
12  2015 Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol. GA
13  2015 Association of cerebral white matter lesions with cognitive function and mood in Japanese elderly people: a population-based study. BP, DWMH, LDL-C, PVH, WMLs
14  2015 Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama Study. FPG, GA, GI, HbA1c, IMT, PG
15  2015 Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: a randomized non-inferior test. GA
16  2015 Glycated albumin is more closely correlated with coronary artery disease than 1,5-anhydroglucitol and glycated hemoglobin A1c. CAD, CSI, GA, HbA1c
17  2015 HOMA-IR Values are Associated With Glycemic Control in Japanese Subjects Without Diabetes or Obesity: The KOBE Study. FPG, HOMA-IR
18  2015 Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk. CAD, HbA1c
19  2015 Rational diagnoses of diabetes: the comparison of 1,5-anhydroglucitol with other glycemic markers. DM, FPG, ROC
20  2015 Reactivity of sorbose dehydrogenase from Sinorhizobium sp. 97507 for 1,5-anhydro-D-glucitol. ---
21  2015 Salivary protein glycosylation as a noninvasive biomarker for assessment of glycemia. CGM, HbA1c
22  2015 Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes. T2DM
23  2015 [THE DIFFERENCES OF TREC (T-CELL RECEPTOR EXCISION CIRCLES) CONCENTRATION IN TYPE 2 DIABETIC PATIENTS]. ---
24  2014 1,5-Anhydro-D-glucitol predicts coronary artery disease prevalence and complexity. CAD, HbA1c
25  2014 1,5-Anhydroglucitol and glycated albumin in glycemia. GA
26  2014 1,5-Anhydroglucitol in saliva is a noninvasive marker of short-term glycemic control. ---
27  2014 Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. CGM, GA, hs-CRP
28  2014 Association of 1,5-anhydroglucitol with diabetes and microvascular conditions. ARIC, HR, OR
29  2014 Association of reduced levels of serum 1,5-Anhydro-d-glucitol with carotid atherosclerosis in patients with type 2 diabetes. IMT, PS
30  2014 Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management. HbA1c
31  2014 Change in urinary N-acetyl-beta-d-glucosaminidase levels relevant to postprandial glycemic control conditions in subjects without diabetes mellitus. DM
32  2014 Comparative associations of diabetes risk factors with five measures of hyperglycemia. ARIC, BMI, HbA1c
33  2014 Effect of repaglinide, administered two or three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus. GA
34  2014 Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes. AUC-PG, BOT, DPP-4i, GA, PG, PI, T2DM
35  2014 Increased circulating RANTES in type 2 diabetes. ---
36  2014 Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy. DPP-4, DPP-4 inhibitor CTG, PPG, T2DM
37  2014 Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes. CGM, L_RHI, RHI, T2DM
38  2014 Postprandial glycemic control conditions in relation to urinary N-acetyl-beta-D-glucosaminidase in patients with type 2 diabetes mellitus without low glomerular filtration rate. HbA1c, NAG
39  2014 The use of 1.5-anhydroglucitol for monitoring glycemic control in islet transplant recipients. ICT
40  2014 Thresholds of various glycemic measures for diagnosing diabetes based on prevalence of retinopathy in community-dwelling Japanese subjects: the Hisayama Study. AUC, DR, FPG, GA, HbA1c, PG, ROC
41  2014 [Indicators of glycemic control --hemoglobin A1c (HbA1c), glycated albumin (GA), and 1,5-anhydroglucitol (1,5-AG)]. AG, GA, NGSP
42  2013 1,5-Anhydroglucitol as a marker of maternal glycaemic control and predictor of neonatal birthweight in pregnancies complicated by type 1 diabetes mellitus. CGMS, ROC
43  2013 1,5-Anhydroglucitol in diabetes mellitus. ---
44  2013 Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. BMI, MAGE, MDI, SMPG
45  2013 Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. 8-iso PGF2alpha, AUC-180, CGMS, CONGA, MAGE, MODD, MPMG
46  2013 Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus. AUC-180, CGMS, FA, HbA1c, MAGE, MAGEgos, MPMG
47  2013 Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. 75-g OGTT, CGMS, NAFLD, NASH, T2DM
48  2013 Protective effects of dietary 1,5-anhydro-D-glucitol as a blood glucose regulator in diabetes and metabolic syndrome. ---
49  2013 Relationship between postprandial glucose level and carotid artery stiffness in patients without diabetes or cardiovascular disease. IMT, PI
50  2013 Serum uric acid in relation to serum 1,5-anhydroglucitol levels in patients with and without type 2 diabetes mellitus. DM, UA
51  2012 A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycaemic excursions as measured by continuous glucose monitoring system among people with type 2 diabetes in China. ---
52  2012 Alternative markers of hyperglycemia and risk of diabetes. A1C, ARIC, HR
53  2012 Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose. AUC
54  2012 Clinical and forensic examinations of glycemic marker 1,5-anhydroglucitol by means of high performance liquid chromatography tandem mass spectrometry. ---
55  2012 Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). AOC, AUC, BNP, CGM, CPR, GA, IRI, MAGE, PAI-1
56  2012 Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study. T2D, VFA
57  2012 Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls. HbA1c, T1D
58  2012 Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. CI, CSII, FA
59  2012 Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes. SMC-DPP
60  2011 1,5-Anhydroglucitol levels are low irrespective of plasma glucose levels in patients with chronic liver disease. CLD
61  2011 A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. CGM, DPP-4, GIP, GLP-1
62  2011 Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus. GLP-1, OHA
63  2011 Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. CGMS, FBG, GA, HbA1c, iAUC, LAGE, MAGE, MBG, MODD, PPGE, SDBG
64  2011 Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests. 2h-PG, min, OGTTs, ROC
65  2011 Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. BIAsp 30, CAVI
66  2011 Nontraditional markers of glycemia: associations with microvascular conditions. ARIC
67  2011 Selective contribution of waist circumference reduction on the improvement of sleep-disordered breathing in patients hospitalized with type 2 diabetes mellitus. AHI, BMI, hs-CRP, SDB, T2DM, TBARS, WC
68  2011 Serum 1,5-anhydro-D-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. CHD, CVD, HRs
69  2011 The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring. AUC, CGM, HbA1c
70  2011 [Development of the novel delivery system of GLP-1 administration for the treatment of diabetes mellitus]. GLP-1
71  2010 1,5-Anhydroglucitol attenuates cytokine release and protects mice with type 2 diabetes from inflammatory reactions. IL, iNOS, LPS, MCP, TNF
72  2010 Habitual intake of dairy products influences serum 1,5-anhydroglucitol levels independently of plasma glucose. ---
73  2010 Lack of correlation between 1,5-anhydroglucitol assay and oral glucose tolerance test in patients with cystic fibrosis. CFRD, IGT, OGTT
74  2010 Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). AG, CGM, CV, GA, SD
75  2010 Serum 1,5-anhydroglucitol levels in patients with fulminant type 1 diabetes are lower than those in patients with type 2 diabetes. FT1DM, T2DM
76  2009 Assessing postprandial glucose using 1,5-anhydroglucitol: An integrative literature review. PPHG
77  2009 Close relationship between serum concentrations of 1,5-anhydroglucitol and uric acid in non-diabetic male subjects implies common renal transport system. ---
78  2009 Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. A1C, MPG
79  2008 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. ---
80  2008 A novel fully enzymatic method for determining glucose and 1,5-anhydro-D-glucitol in serum of one cuvette. GK
81  2008 Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. ---
82  2008 Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1alpha maturity-onset diabetes of the young. HNF-1alpha, MODY, ROC
83  2008 Comparison of pre- vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients. alpha-GIs
84  2008 Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naive type 2 diabetic patients. BB, BMI, ITR-QOL, QOL
85  2008 Determination of glycemic monitoring marker 1,5-anhydroglucitol in plasma by liquid chromatography-electrospray tandem mass spectrometry. ---
86  2008 Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. BIAsp 30, IGlar, PPG
87  2007 Hyperglycemia and diabetic renal change in a model of polyvinyl alcohol bioartificial pancreas transplantation. ---
88  2007 Pro-atherogenic alterations in T-lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients. DM
89  2007 Serum 1,5-anhydroglucitol (Glycomark) levels in children with and without type 1 diabetes mellitus. T1DM, T2DM
90  2006 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. AUC-180, CGMS, FA, MPMG
91  2006 Plasma anhydro-D-glucitol (1,5-AG) as an indicator of hyperglycaemic excursions in pregnant women with diabetes. MBG, MxG
92  2006 Short term intensive insulin therapy improves insulin secretion significantly in type 2 diabetic patients. AUCglucose, AUCinsulin
93  2005 Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. FFA, FPG, HDL
94  2005 The application of plasma 1,5-anhydro-D-glucitol for monitoring type 2 diabetic patients. FG, MBG, MxG
95  2004 Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. ---
96  2004 Different effects of two alpha-glucosidase inhibitors, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level. Aca, alpha-GIs, FPG, GC/MS, VOG
97  2004 Evaluation of an assay for serum 1,5-anhydroglucitol (GlycoMark) and determination of reference intervals on the Hitachi 917 analyzer. ---
98  2003 1,5-Anhydroglucitol stimulates insulin release in insulinoma cell lines. ---
99  2003 A novel NAD-dependent dehydrogenase, highly specific for 1,5-anhydro-D-glucitol, from Trichoderma longibrachiatum strain 11-3. AGH, SDS-PAGE
100  2003 Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. ---